Phase 1 Trial of Alzheimer’s Candidate SM07883 Doses First Participant
A Phase 1 trial evaluating Samumed’s investigational compound SM07883 for Alzheimer’s disease has dosed its first participant. The Phase 1 trial (ACTRN12619000327189), taking place in Australia, will assess the safety, tolerability, and pharmacokinetics (the movement of a medicine into, through, and out of the body) of ascending doses…